Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Wilkerson, Matthew D ^a   Yin, Xiaoying ^a   Walter, Vonn ^a,b   Zhao, Ni ^a,b   Cabanski, Christopher R ^a,c   Hayward, Michele C ^a   Miller, C Ryan ^a,d   Socinski, Mark A ^a,d   Parsons, Alden M ^d   Thorne, Leigh B ^a,d   Haithcock, Benjamin E ^d   Veeramachaneni, Nirmal K ^d   Funkhouser, William K ^a,d   Randell, Scott H ^a   Bernard, Philip S ^e   Perou, Charles M ^a,d   Hayes, D Neil ^a,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; EGFR GENE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE K RAS; OVERALL SURVIVAL; STK11 GENE; TP53 GENE; ADENOCARCINOMA; AGED; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENE DOSAGE; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SURVIVAL RATE;

DNA;

ADENOCARCINOMA; AGED; CHROMOSOMAL INSTABILITY; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; SURVIVAL RATE;

EID: 84861004486     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036530     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, et al. (2009) An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28: 2773-2783.
3. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, et al. (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119: 1727-1740.
4. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, et al. (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102: 9625-9630.
5. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
6. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
7. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873.
8. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, et al. (2006) Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 24: 1679-1688.
9. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, et al. (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358: 1118-1128.
10. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, et al. (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824.
11. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98: 13790-13795.
12. Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, et al. (2010) Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 5: e11712.
13. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, et al. (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 98: 13784-13789.
14. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, et al. (2006) Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24: 5079-5090.
15. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, et al. (2007) Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 13: 2946-2954.
16. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, et al. (2008) Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32: 810-827.
17. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
18. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, et al. (2009) Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27: 2793-2799.
19. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
20. Janku F, Stewart DJ, Kurzrock R, (2010) Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 7: 401-414.
21. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, et al. (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8: 740-801.
22. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, et al. (2011) The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery 1: 44-53.
23. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, et al. (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-2127.
24. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, et al. (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17: 547-559.
25. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, et al. (2010) Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28: 4417-4424.
26. Yuan E, Haghighi F, White S, Costa R, McMinn J, et al. (2006) A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons. Cancer Res 66: 3443-3451.
27. Wang K, Li M, Hakonarson H, (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164.
28. Wilkerson MD, Hayes DN, (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26: 1572-1573.
29. Dabney AR, (2006) ClaNC: point-and-click software for classifying microarrays to nearest centroids. Bioinformatics 22: 122-123.
30. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, et al. (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70: 3463-3472.
31. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, et al. (2010) Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2: 38ra47.
32. Walter V, Nobel AB, Wright FA, (2011) DiNAMIC: a method to identify recurrent DNA copy number aberrations in tumors. Bioinformatics 27: 678-685.
33. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, et al. (2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4: 521-528.
34. de Wilde J, Kooter JM, Overmeer RM, Claassen-Kramer D, Meijer CJ, et al. (2010) hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer 10: 271.
35. Weiss MB, Vitolo MI, Mohseni M, Rosen DM, Denmeade SR, et al. (2010) Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene 29: 4715-4724.
36. Hastak K, Alli E, Ford JM, (2010) Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 70: 7970-7980.
37. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, et al. (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6: 276.
38. Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, et al. (2011) Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat.
39. Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M, (2010) Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23: 159-168.
40. Barletta JA, Yeap BY, Chirieac LR, (2010) Prognostic significance of grading in lung adenocarcinoma. Cancer 116: 659-669.
41. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, et al. (2009) Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 4: e7464.
42. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
43. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793.
44. Stratton MR, Campbell PJ, Futreal PA, (2009) The cancer genome. Nature 458: 719-724.
45. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T, (2005) EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29: 633-639.
46. Bengtsson H, Wirapati P, Speed TP, (2009) A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 25: 2149-2156.
47. The Cancer Genome Atlas Research Network, (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
48. Monti S, Tamayo P, Mesirov J, Golub T, (2003) Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Machine Learning 52: 91-118.
49. Liu Y, Hayes DN, Nobel A, Marron JS, (2007) Statistical Significance of Clustering for High Dimension Low Sample Size Data. Journal of the American Statistical Association 103: 1281-1293.